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In 2010, in Osteoarthritis and Cartilage, we published a comprehensive systematic review applying the
consensus BIPED criteria (Burden of Disease, Investigative, Prognostic, Efﬁcacy of Intervention and
Diagnostic) criteria on serum and urinary biochemical markers for knee and hip osteoarthritis (OA) using
publications that were available at that time. It appeared that none of the biochemical markers at that
time were sufﬁciently discriminating to allow diagnosis and prognosis of OA in individual or limited
numbers of patients, nor performed so consistently that they could function as primary outcome pa-
rameters in clinical trials. Also at present, almost 3 years later, this ultimate goal has not been reached
(yet). Frankly, it might be questioned whether we are making the most adequate steps ahead and maybe
we have to take a step back to reconsider our approaches.
Some reﬂections are made and discussed: A critical review of molecular metabolism in OA and vali-
dation of currently investigated marker molecules in this may be vital and may lead to new and better
markers. Creating cohorts in which synovial ﬂuid (SF) is obtained in a systematic way, together with
serum and urine, may also bring the ﬁeld a further step ahead. Thirdly, better understanding of different
phenotypes (subtypes) of OA may facilitate identiﬁcation and validation of biochemical markers. Finally,
the systems biology approach as discussed in the last years OA in review on biomarkers, although very
complex, might provide steps forward.
Looking ahead, we are optimistic but realistic in our expectations, we believe that the ﬁeld can be
brought forward by critically and cautiously reconsidering our approaches, and making changes forward,
one step at a time.
 2013 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.In 2010, in Osteoarthritis and Cartilage1, we published a
comprehensive systematic review applying the consensus BIPED
criteria (Burden of Disease, Investigative, Prognostic, Efﬁcacy of
Intervention and Diagnostic) criteria2 on serum and urinary
biochemical markers for knee and hip osteoarthritis (OA) using
publications that were available at that time. It appeared that none
of the biochemical markers at that time were sufﬁciently discrim-
inating to allow diagnosis and prognosis of OA in individual or
limited numbers of patients. Also none of themarkers performed so
consistently that they could function as primary outcome param-
eters in clinical trials. More research on molecular validation and
origin(s) and metabolism of biochemical markers was deemed
necessary. Also, especially wide-spectrum biochemical marker
analysis in well-deﬁned populations, preferably with protocolisedF.P.J.G. Lafeber, Rheumatology
t, PO Box 85500, 3508 GA
feber).
s Research Society International. Psample collection, was considered valuable. Together, these aspects
were expected to clarify many unknowns about biochemical
markers that hampered progression of the ﬁeld. In the OA year of
review, every year since, the value of reliable biochemical markers
(and biomarkers in general) that would enable diagnosis, prognosis
and monitoring of treatment effect at the individual level was
stressed3,4,5. Nevertheless, at present, almost 3 years later, this ul-
timate goal has not been reached (yet). Frankly, it might be ques-
tioned whether we are making the most adequate steps ahead and
we may have to take a step back to reconsider our approaches.
For the current review, we assessed the literature from January
2012 until March 2013 on ‘PubMed’ using the terms ‘osteoarthritis’
or ‘cartilage damage’ and ‘biomarkers’ (for all three, related terms
such as ‘osteoarthrosis’ or ‘joint damage’ or ‘biochemical marker’, in
singular and plural, were used as well). This revealed 914 hits that
were screened by title for studies on biochemical markers in OA. In
a next step, the abstracts of a total of 91 remaining studies were
screened and 61 relevant publications were selected (compiled in
Tables IeV). Table I contains 27 publications on markers in serum,
plasma and/or urine, and Table II contains 12 publications ofublished by Elsevier Ltd. All rights reserved.
Table I
Serum, plasma and/or urine protein biochemical marker analyses (January 2012eFebruary 2013 studies) ordered according to the BIPED classiﬁcation
Molecules Population Investigative Diagnostic Burden Prognostic Efﬁcacy
54 s proteomic approach with
sequential depletion, 2D gel
electrophoresis
20 knee or hip OA vs 20 HC Eight proteins increased and seven decreased
distinguished between OA and HC; amongst
them haptoglobin-beta chain
55 p N-glycoproteomic analyses
(2D-LC-MALDI)
Three knee OA R progressors
vs non-progressors
clusterin, hemopexin, a1 acid glycoprotein 2,
macrophage stimulating protein from 3000 MS
peaks were discriminative
26 uCTX-II, uNTXI, sPINP, sOC,
sCOMP, sCS846, sPIIANP
1002 Participants with early
signs of knee and/or hip OA
(CHECK)
uCTX associated with bone markers (all showing
menopausal shift) more than cartilage markers
25 uCTX-II, uCTX-I, uNTX-I,
sCOMP, sPIIANP, sCS846,
sC1, 2C, sOC, sPINP, sHA,
sPIIINP, pLeptin,
pAdiponectin, pResistin
1002 participants with early
signs of knee and/or hip OA
(CHECK)
‘Bone-CTX-II’, ‘inﬂammation’, ‘synovium-sCOMP’, ‘C1,
2C-adipokines’, and ‘cartilage synthesis’ cluster
identiﬁed
53 sCOMP, uCTX-II R hand OA in 329 longevity
cohort vs 329 healthy agers
and vs 192 generalised OA
cohort
sCOMP and UCTX-II increase with aging and depend
on metabolic health
60 s a2HS-glycoprotein (AHSG)
and BMP-2, 4, 7
Joint degeneration of 15 hip
and 15 TMJ joints for
arthroplasty vs 120 HC
BMP2 and 4 higher in patients AHSG lower in patients
(blood sampling after prosthesis)
52 sMMP-13/sColl2-1 (and 10
others) in mtDNA
haplogroups H and J
48 Knee or hip OA vs 52 HC Haplogroup H þ MMP-13 and Coll2-1
Haplogroup J þ MMP-13 discriminated
OA from HC
42 u proteomics 2D gel
electrophoresis,
identiﬁcation by mass
spectrometry, veriﬁcation
by ELISA
10 OA for TKP and ﬁve HC
ELISA veriﬁcation in 76
severe knee OA vs 236 HC
Fib3-1 and 3-2 discriminated OA from
HC
61 s LDL, HDL, cholesterol, MDA
(malondialdehyde; oxidative
stress indicator), CRP,
triglyceride, uric acid, total
lipid
28 OA, (36 RA) vs 36
matched HC
LDL, HDL, cholesterol, MDA, CRP,
triglyceride discriminated between OA
and HC (most of them in RA even higher)
62 sVit-D(25(OH)D) 190 hand OA population
with varying R-severity
Not (KeL or OP) Not with KeL or OP
63 uCTX-II 125 Knee OA vs 57 HC Discriminated OA from HC Not with R JSW
64 (Chinese) sCOMP 115 knee OA varying R-
severity vs 35 HC with
follow-up
Yes (including R-OA prediction in case of
sub-clinical OA)
With KeL grade
65 s ucOC, sNTx, s bone AP, sCPII,
sHA, uCTX-II
25 bilateral knee OA with
varying sum KeL grade
s-ucOC, sCPII, sHA, and uCTX-II
discriminated OA from HC
Not with KeL sum score
29 p (fasted) phospholipid n6
and n-3 PUFAs
472 (risk for) knee OA n6 PUFAs with synovitis
n3 PUFAs with only PF
cartilage only on MRI
34 sColl2-1, sColl2-1NO2, s MPO 57 EHOA vs 20 non-erosive
hand OA
MPO discriminated
EHOA from non-EHOA
and correlated with
hsCRP
33 sCOMP, sHA, sC2C, sCP-II,
uCTX-II, uNTX-I
547 individuals evaluated
for lumbar spine DSN and
OP
sHA uCTX-II correlated
with DSN
uCTX-II correlated with OP
66 sCRP and ESR 285 Knee OA Association of CRP and ESR
with lower muscle strength,
lost when BMI corrected
(continued on next page)
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Table I (continued )
Molecules Population Investigative Diagnostic Burden Prognostic Efﬁcacy
67 s aggrecan epitopes NITEGE
and ARGSVI vs uCTX-II
125 knee OA vs 57 HC Both were decreased in OA vs HC whereas
uCTX-II was increased in OA vs HC
Min JSW correlated with
both, no correlation with
uCTX-II
7 S COMP fragments 57 knee OA vs 21 HC COMP fragment discriminated between OA
and HC whereas COMP did not
COMP fragment related to
KeL grade
43 sS100A8/S100A9 10 OA for TKP and very early
OA (CHECK) 95 non-progress
vs 82 progress over 2 yrs
sS100A8/S100A9 correlation
with synovial activity and
cartilage damage
Higher levels in those
who progressed over
2 yrs
51 sCOMP, uCTX-II, sPIIANP 128 individuals with risk of
knee OA over 6 yrs
All three at different time
points with severity of OP
and COMP and CTX-II with
severity of OA
BL COMP associated
with progression of
OP early in disease
CTX-II associated
with progression of
OP and JSN later in
disease
32 pLeptin, pAdiponectin,
pResistin vs uCTX-II,
sPIIANP, sCS846, sCOMP,
sHA, sPIIINP
1002 individuals with early
signs of knee and/or hip OA
(CHECK) with KeL grading
over 5 yrs
pLeptin pResistin with presence of ROA
(stronger in case of high pAdiponectin)
pLeptin with
progression of ROA
pResistin with
incidence of ROA
45 s hsCRP, sTNFa, sIL-6 149 individuals over 5 yrs BL, and D2.7 yr in
hsCRP, TNFa and IL-6
ROA independently
associated with change
in knee (WOMAC) pain
30 s COMP 17 Medial compartmental
knee OA
Change in COMP post-
activity (adjusted for
age, sex, and BMI)
correlated with changes
in MRI cartilage thickness
after 5 yrs in contrast to
BL COMP
58 p soluble TNFaR1 and
sTNFaR2
Knee OA control (11) vs
squat exercise without (10)
and with vibration (11) 3
wk for 12 wks
Decrease in both TNFR
upon platform squat
exercise
57 sYKL-40 and hsCRP 44 Knee OA treated with
mud pack (23) or heat pack
(21) 3 mths follow-up and
26 HC
YKL-40 and hsCRP discriminates OA from HC Mud pack stabilised
YKL-40 in hot pack it
increased
35,89 sC2C, sCOMP, sHA, CS846,
sCol-II pro pep, and
uCTX-II as well as Coll2-1
and Coll2-1-NO2
45 knee OA with HA i.a.
treatment 3 mths follow-up
uCTX-II with walking pain
baseline Coll2-1(NO2)
with KeL grade
Decrease in uCTX-II
and Coll2-1 correlated
with clinical response.
uCTX and sHA
predictors of response
s, serum; p, plasma; u, urine; R, radiographic; ms, manuscript; TKP, total knee prosthesis; BL, baseline; HC, healthy controls; JSW, joint space width; wks, weeks; yrs, years; vs, versus; COMP, cartilage oligomeric matrix protein;
CTX, cross linked C-telopeptide of collagen.
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Table II
SF protein biochemical marker analyses (January 2012eFebruary 2013 studies) ordered according to the BIPED classiﬁcation
Report Molecules Population Investigative Diagnostic Burden Prognostic Efﬁcacy
41 SF 2D electrophoresis with (LCMS) mass
spectrometry
ﬁve knee OA KeL 2e4 Multiple proteins
including plasma
proteins with pro-
inﬂammatory activity
68 SF Luminex (10 and seven plex) and
Meso Scale Discovery (MSD) four plex
multiplex protein platforms (IL1-b, IL-6,
TNF-a, IL-4, IL-8, IL-10, GM-CSF, IL-5,
IFN-g, IL-2)
7e16 knee OA for TKP Hyaluronidase treatment
improved analytical
methods
6 SF tenascin-C, ARG-, 846-, and F-21-
aggrecan, MMP-1, and -3, TIMP-1, PCIIC,
COMP, CTX-II
164 knees (HC, ACL rupture,
meniscus lesion, inﬂammatory
arthritis, OA)
Association between
tenascin-C and ARG-
aggrecan, MMP-1, and -3
Discriminated between disease and HC
44 SF S100A12 þ two unknown 36 OA for TKP vs 24 RA for TKP Discriminating OA from RA
40 SF HA and protein composition and
viscosity
Knee OA 19 with a ﬂare vs 25
without ﬂare
All discriminated ﬂare from none-ﬂare
8 SF, p, u NT, No(x), MMP-3, -1, -9 þ>40
chemokines and cytokines
OA, RA, ACL injury, meniscus
injury, pseudogout, and HC
SF and p NT discriminated OA vs HC
(best for SF) and correlated with cartilage
degradation markers (much higher in RA)
69,70 SF soluble CD14 30 Early OA for meniscectomy,
seven advanced OA for TKP, six
RA for TKP and 10 asymptom HC
SF soluble CD14 discriminated OA from
HC but not from RA
71 SF full length and thrombin cleaved OPN 175 Primary knee Thrombin cleaved OPN
correlated with R JSW
10 SF and serum RANKL 20 Primary knee OA (of which 11
with EHOA) vs 13 HC
sRANKL discriminated OA (lower) from
HC
SF RANKL correlated with
KeL score, EHOA, and
Heberden and Bouchard
nodes
9 SF and serum CXCL12 (stromal cell
derived factor, the ligand of CXCR4)
252 Knee OA vs 144 HC sCXCL12 discriminates OA from HC SF CXCL12 correlated with
KeL grade
39 SF IL-6. IFNy, MCP-1, MIP-1b, and
FAC; matrix degradation marker
Ankle OA in different degrees of
severity: n ¼ 4, 11, 6, 15, and 4
Discriminative between HC and OA:
FAC, IL-6, and MCP-1
FAC and MCP-1 correlated
with increase with severity
56 SF C6S, C4S, KS 25 OA knees with arthroscopy
BL and repeatedly over time
for 12 wks
KS and ratio C6S/
C4S decreased
upon arthroscopy
over time
ACL, anterior cruciate ligament; s, serum; p, plasma; u, urine.
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Table III
Genetic markers (January 2012eFebruary 2013 studies) ordered according to the BIPED classiﬁcation
Report Molecules Population Investigative Diagnostic Burden Prognostic Efﬁcacy
72 SNP Sterol Regulatory
Element Binding Protein-2
(SREBP-2)
709 Knee OA for
TKP vs 701 HC
SREBP-2 discriminates OA from HC
73 SNP IL-18 and IL-18R1 160 knee OA vs
198 HC
IL-18 (only) discriminates OA from
HC
74 Eight NFKB1A
polymorphisms and s HA,
CRP, KS, and GAG
189 Knee OA vs
197 HC
rs8904 was associated with
increased sHA and rs696 with
CRP
Variant rs8904 was discriminative
between OA and HC only in women
71 Three OPN SNP and cleaved
OPN
750 Primary
knee OA vs 794
HC
Two SNPs showed lower
thrombin cleaved OPN SF levels
Two SNPs discriminated OA from
HC
Two SNPs were
associated with
lower KeL grade
OPN, osteopontin; SNP, single nucleotide polymorphism; .
F.P.J.G. Lafeber, W.E. van Spil / Osteoarthritis and Cartilage 21 (2013) 1452e14641456markers in synovial ﬂuid (SF), all in humans. Table III shows four
publications on genetic markers. Animal studies on biochemical
markers, 12 in total, are presented in Table IV. Finally, three publi-
cations on biochemical markers after prosthetic surgery have been
gathered in Table V. Two publications combined human and animal
work6,7 and three combined analyses in the peripheral (serum)
compartment with the joint (SF) compartment8e10 (presented in
Table II). The publications are ordered in the tables according to the
“BIPED” biomarker classiﬁcation (which stands for Burden of
Disease, Investigative, Prognostic, Efﬁcacy of Intervention and
Diagnostic).2
Selection was restricted to biomarkers in blood, urine, and SF.
Publications on biomarkers in cartilage, bone, or synovial tissue
samples were not included, although some of them contain inter-
esting data on markers that could have been classiﬁed as ‘investi-
gative’ according to the BIPED classiﬁcation11e16. Publication solely
in abstract format was not included either. Despite our best effort,
relevant publications might have been missed.
In addition eight reviews have been published in the past year.
One on serological markers of erosive hand OA (EHOA)17, a more
speciﬁc one on transglutaminase 2 as a biomarker of OA18, one on
mitochondrial (mt) genetics of OA19, one on the potential impor-
tance of endotoxaemia and low-grade chronic inﬂammation20, one
on the impact of treatment for osteoporosis on cartilage biomarkers
in humans21, one on obesity related inﬂammation and OA22 and
two more classical overviews on biological markers of OA23 and on
prognostic biomarkers in OA24. Speciﬁcally the latter two publica-
tions provide (very recent) comprehensive overviews of the
currently available literature. Therefore, in the current overview
only a selection of the publications concentrated in the tables is
described in the main text, taking the liberty, in all modesty, to
discuss these studies in the context of, to a certain extent, pro-
vocative suggestions. We choose to address the items, indicated by
the headings of the subsequent paragraphs.
Molecular validation; what have we learned from the past
year?
In 2010, we suggested that more research on molecular valida-
tion and the origins and metabolism of biochemical markers was
necessary. As became apparent from our literature search, this was
clearly not the main topic of any of the selected publications.
However, the importance of this issue is illustrated by observations
on the molecular validity/origin of (urinary) uCTX-II. uCTX-II was
originally meant to reﬂect collagen type II degradation in cartilage,
a prominent feature in OA. uCTX-II became one of the best ‘per-
forming’ and one of the most frequently studied commercially
available biomarker. However, recently principal component anal-
ysis of 16 commercially available biochemical markers in 1002individuals with early signs of knee and/or hip OA (Cohort Hip &
Cohort Knee; CHECK) showed that uCTX-II clustered with markers
of bone metabolism (i.e., uNTXI, uCTXI, serum (s)PINP, and sOC)
rather thanwith those of cartilage metabolism25. uCTX-II was more
strongly associatedwith these bonemarkers thanwith the cartilage
markers (sPIIANP, sCS846, sCOMP), while the ‘other’ cartilage
markers were not so strongly associated with the bone markers26.
Moreover, it was demonstrated that, both uCTX-II and bone
markers but not cartilage markers showed an abrupt menopausal
increase inwomen, independent of age and body mass index (BMI).
Indeed, as was recently reviewed21, almost all anti-resorptive
agents, including the recently published strontium ranelate27,
affect uCTX-II levels. Obviously, any similarity between uCTX-II and
bone markers could be attributable to a link between cartilage and
bone metabolism (through metabolic and biomechanical mecha-
nisms). Alternatively, especially in the context of less well per-
forming ‘other’ cartilage markers, uCTX-II might not only reﬂect
bone but also cartilage metabolism. Therefore, cautious interpre-
tation of CTX-II levels as marker of (only) cartilage breakdown is
needed and more thorough molecular validation of uCTX-II war-
ranted. It should be noticed that the lack of cartilage speciﬁcity for
uCTX-II, maybe more critical for diagnostic and burden of disease
classiﬁcations and maybe less so for prognostic or efﬁcacy appli-
cations. More earlier publications address in more detail CTX-II its
principal origins, such as osteophytes (OP) and calciﬁed articular
cartilage. Also, this issue is not restricted to CTX-II; one can say the
same for cartilage oligomeric matrix protein (COMP) that is syn-
thesised and secreted by many tissues, especially inﬂamed syno-
vium. However, an in-depth review of all literature on these items
was considered beyond the scoop of the present review. Below, two
studies on COMP metabolites are described that also support the
importance of this issue for all biochemical markers7,28. In some
cases antibodies are raised against synthetic epitopes of the
molecule of interest. These constructed epitopes are not always
identical to the in vivo circulating epitopes which also may differ
between the different compartments (SF, serum, or urine). This
with the above examples stresses the importance of molecular
validation and study on the origins of biochemical markers.
Wide-spectrum marker sets, well-deﬁned cohorts, and
protocolised sampling; what did they bring us?
Wide-spectrum biochemical marker analysis in well-deﬁned
populations, preferably with protocolised sample collection, was
considered valuable as well1. To the best of our knowledge, among
the selected publications, only Baker29 stressed the use of early-
morning, fasted sample collection. They investigated associations
of fatty acids with structural tissue changes in 472 subjects at risk of
developing knee OA (Multicenter Osteoarthritis Study; MOST).
Table IV
Animal studies on biochemical markers (January 2012eFebruary 2013 studies) ordered according to the BIPED classiﬁcation
Report Molecules Population Diagnostic Burden Prognostic Efﬁcacy
75 Loci at chromosome 4 and 5
(D4Mit97 and D5Mit223)
Mice: (STR/ort) spontaneous OA Discriminated cartilage
degeneration vs no degeneration
76 SerumNMRmetabolic ﬁngerprint
response
Sheep: sham, MD, or ACLT pre-
and 4 and 12 wks post-surgery
samples (all n ¼ 6)
In MD: DMSO2 increased
In ACLT: 3-methylhistidine
increased and branched chain
amino acids decreased
6 SF tenascin-C, ARG-, 846-, and F-
21-aggrecan, MMP-1, and -3,
TIMP-1, PCIIC, COMP, CTX-II
Dogs: ﬁve ACLT vs contra lateral
HC
Tenascin-C discriminated ACLT
from HC
77 Serum Coll2-1, Coll2-1NO2 MPO Dogs: 16 ACLT dogs over 8 wks sColl2-1, Coll2-1NO2, and MPO
increased
sColl2-1 relation with structural
damage; Coll2-1NO2 related with
OP formation
78 Serum xylosyltransferase 1
(Xylt1; key in GAG chain
synthesis), C12C, and OC
Mice: MM vs shammice C57BL/6J
(high bone remodelers; slow
progressors) and C3H/HeJ (high
bone formers; fast progressors)
over 3, 5 mths
Only sXylt1 only elevated in fast
progressors only early in the
disease
sXylt1 related to severity of tissue
damage early in disease in fast
progressors
7 Serum COMP fragment Mice MD and partial MM-ectomy
vs controls
Discriminated OA from controls Increased with time after surgery
related to Mankin grade cartilage
damage
79 SF GAGs: HA (mw) and CS, and
WBC count.
Horses: 11 asymptomatic, 25
symptomatic OCD vs 10 HC
HA and CS discriminative
HA mw decreased, WBC count
increased
CS elevated in
asymptomatic
80 SF IL-1b, TNFa, IL-6, MMP-3, and
GAG
Dogs 31 with CL rupture treated
with osteotomy repeated
sampling over 6 mths follow-up
IL-6, TNFa, and IL-1b decreased
over time, cartilage damage
increased
81,82 Serum KS, HA, CS846 plasma
amino acid conc
Rabbits: 12 ACLT with and
without three different
treatments (four groups each
n ¼ 3)
For sKS, sHA, CS846 no difference
whereas for alanine, threonine,
and methionine there was a
difference between pre- and post-
ACLT
Some amino acids changed with
interventions
83 Transcriptomics of blood
leucocytes (RNA microarray and
qPCR validation)
Dogs: six OA affected with NSAID
(Firocoxib) vs six HC dogs (BL and
20 days blood samples)
IL18, IL8, S100A8, S100A9 and
TNFa discriminated OA from HC
IL8, Il-18, TNF (en TLR4 þ COX2)
down regulated by treatment
84 SF proteomic analyses (2D gel
electrophorese, identiﬁcation by
mass spectrometry)
Horses: 10 OA vs 10 HC as well as
10 OC i.a. injection with
conditioned medium every wk up
to 3 mths
For OA vs HC discriminating: ITI-
H1; APOA1; a2-MG;
serotransferrin; antithrombin III;
a1B-G; IGg-Hc1; IgGg-Hc5; HP;
ceruloplasmin; C4A; afamin;
carboxylesterase D1;
plasminogen; VitD-BP; TTR;
serum albumin.
C4A; carboxylesterase D1; a2-
MG; ceruloplasmin;
serotransferrin; APOA1 changed
toward normal by autologous
conditioned medium treatment
85 Serum COMP, MMP-3, TNFa, IL-
1b, IL-17, PGE2
Mice: (STR/ort) spontaneous OA
with follow-up; treated with tin
protoporphyrin IX (SnPP)
sMMP-3 (only) increased at 9 wks
as did histological cartilage
damage
SnPP decreased MMP-3 at 9 wks
and limited cartilage damage
MM, medial meniscectomy; OC (D), osteochondrosis (dissecans); ACLT, anterior cruciate ligament transection; CL, cruciate ligament; MD, meniscal destabilisation; .
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Table V
Studies on prosthetic surgery and biochemical markers (January 2012eFebruary 2013 studies) ordered according to the BIPED classiﬁcation
Report Molecules Population Investigative Diagnostic Burden Prognostic Efﬁcacy
86 Plasma markers of the
clotting cascade
110 Hip or knee OA for TP No abnormalities
87 SF monocyte chemotactic
protein (MCP-1)
Six aseptic loosening of TKP vs
10 OA and four RA
MCP-1 was discriminative
in TKP loosening vs OA
and RA
88 Serum chrome and cobalt TKP and THP after 1 yr Serum metal ion
levels related to
persistent pain
TP, total prosthesis, THP, total hip prosthesis; yr, year.
F.P.J.G. Lafeber, W.E. van Spil / Osteoarthritis and Cartilage 21 (2013) 1452e14641458Another important element of this study was that it assessed tissue
structure changes, including inﬂammation, using magnetic reso-
nance imaging (MRI). In the past year, only one additional, small
but interesting, study by Erhart-Hledik and colleagues30, described
in more detail below, used MRI for evaluation of structural damage.
Baker and colleagues found an inverse association between total
levels of omega-3 polyunsaturated fatty acids (PUFAs) with patella-
femoral (PF) cartilage loss, but not with tibio-femoral (TF) cartilage
loss or synovitis, whereas n-6 PUFA was positively associated with
synovitis. It could be concluded that systemic levels of n-3 and n-6
PUFAs, both inﬂuenced by diet, maybe related to selected structural
ﬁndings in knees with or at risk of OA. As such, different pheno-
types of OA, patello-femoral or tibio-femoral, with or without
inﬂammation could be characterised by different systemic
biomarker proﬁles. This study demonstrates that by protocolised
sampling the inﬂuence of food intake can be overcome and how
MRI expands the spectrum of structural parameters that can be
assessed.
In the past year, there were two more studies performed in
comparably large cohorts, both studies evaluating multiple bio-
markers. In 1002 subjects of CHECK (the Dutch early-stage OA
cohort31), plasma adipokines (leptin, adiponectin, and resistin)
were demonstrated to have minor aggravating effects on tissue
structure in early-stage knee OA32. The additive value of assessing
and combining multiple markers was supported by the observation
that the association of resistin with the presence of radiographic
knee OA was stronger when adiponectin levels were higher, while
adiponectin on itself did not show associations with radiographic
knee OA. The other large study investigated lumbar spine disk
space narrowing (DSN) and osteophyte formation in 547 partici-
pants. Among the markers that were evaluated (sCOMP, sHA, sC2C,
sCPII, uCTX-II, and NTXI), sHA and uCTX-II were associated with
DSN and uCTX-II with OP formation, and some gender and ethnic
speciﬁcities were observed33. It conﬁrms that biomarkers can
differently be involved in different pathologic processes, that may
differ between phenotypes and over the course of disease.
In general, looking back over the past 3 years, considering our
conclusions and suggestions at the time of our ﬁrst review, steps
ahead seem small. Expectations of the upcoming wide-spectrum
biomarker assessment in the large OsteoArthritis Initiative (OAI)
cohort are high. Still, in addition, it may become time to critically
and cautiously reconsider our approaches.
Systemic vs local sampling; pros and cons
Most connective tissue components are widespread throughout
the body and are present not only in joint tissues but in other tissues
as well. Therefore, potentially limited tissue speciﬁcity of any tissue
component that is tested as biochemical marker should always be
taken into account when interpreting its levels in blood and urine.
For any biochemical marker to be of use in OA research and clinics,
its release fromOAaffected tissuesmust overwhelm its release fromother connective tissues. For example, since skeletal bone volume is
so large and since bone is rather dynamic as compared to articular
cartilage, putative CTX-II fragment release from bone, even in for
this bone-compartment relative limited amounts, may overwhelm
CTX-II release from articular cartilage. Moreover, biochemical
markers do not only need to be speciﬁc for joint tissues, but should
be sufﬁciently speciﬁc for the disease also. Currently available
biochemical markers do in themselves not distinguish between
healthy and affected joint tissues. As a consequence, they reﬂect
matrix metabolism in not one but all joints in the body when
assessed systemically. Neither do they take into account that basal
levels of matrix turnover may differ between subjects, independent
of OA status. They do not take into account that pathologic turnover
in smaller joints (e.g., the hand) has to ‘compete’ with physiologic
turnover in all the other (larger) joints in the body. All these issues
may be less relevant when destructive processes are very promi-
nent, as has been shown by comparison of erosive and non-erosive
hand OA for plasmamyeloperoxidase (MPO) a protein of circulating
polymorphonuclear cells34. Using (current) systemic biochemical
markers for assessing responses to local therapeutics is complicated
as well, since confounding by marker release from other joints
cannot be ruled out. This may explain the contradicting ﬁndings on
uCTX-II levels upon intra-articular injection with hyaluronic acid
(HA), with Conrozier ﬁnding a decrease of uCTX-II35 and Gonzalez-
Fuentes showing an increase.36
Biochemical marker levels at distance from the joint, in blood
and urine, need to relate to local joint conditions. Challenging in this
respect is that ﬂuctuating joint movement and intermittent syno-
vitis for example, may cause the biochemical marker release from
joint tissues into SF to vary over time. Subsequently, once in the
peripheral blood, biochemical markers are subject to systemic
distribution, metabolism, and excretion. This may especially be
relevant in typically obese and middle-aged or older OA patients,
since they may have different distribution volumes and impaired
hepatic and renal function. To circumvent this, it might be consid-
ered to evaluate systemic markers of local processes after a ‘chal-
lenge’ of these local processes as suggested by Andriacchi37.
Systems level analysis using a stimuluseresponse modelling (e.g.,
upon a short exercise) could increase sensitivity of biomarkers.
Using this approach, this group demonstrated that changes in
COMP levels 3.5 h and 5.5 h after a 30-min walking activity were
correlated with changes in MRI cartilage thickness in the medial
femur and tibia at the 5-year follow-up. The association turned even
stronger after adjustment for age, sex, and BMI. Neither baseline
pre-activity COMP levels nor changes in COMP levels immediately
post-activity were correlated with cartilage thickness changes. It
was concluded that assessing stimulus-response sensitive
biochemical markers in stimulus-response models may improve
prediction of progression of OA by such biochemical markers30.
Although we generally appreciate that biochemical markers
need to function under practically feasible conditions and that
widespread introduction of a biochemical marker in OA research
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a safe, comfortable, and quick procedure) this might be an insu-
perable challenge at this time. Diurnal variability, food intake, and
comorbidities as mentioned above, need to be taken into account
as they will distort the mostly weak associations of systemic
biochemical marker levels with local joint features. In general, as-
sociations between SF and peripheral blood levels of currently
available biochemical markers are weak e.g., Ref. 38. As a conse-
quence, associations between systemic biochemical marker levels
and features of OA in the joint can be expected to be comparably
weak at most. If a putative, systemically assessed, biochemical
marker does not change upon joint replacement surgery (removing
the affected joint) its relevance for clinical practice may be argued.
Surprisingly (unfortunately), the number of studies using this
approach is limited.
Three studies last year used combined local and systemic
biomarker assessment. Xu and colleagues9 found that CXCL12
levels when assessed in SF of knee OA patients were signiﬁcantly
correlated with Kellgren and Lawrence (K-L) grading criteria, but
not when assessed in serum. Ellabban and colleagues10 found that
serum receptor activator of nuclear factor kappa-B ligand (RANKL)
levels discriminated between controls and hand OA but were in-
dependent of clinical, laboratory, or radiological data, while SF
levels were statistically signiﬁcantly higher in patients with
Heberden and Bouchard nodes, higher K-L score, and erosive
changes. They concluded that RANKL is an important marker of
disease severity when assessed in SF but that serum levels of
RANKLwould be of low beneﬁt in this respect. SF nitrotyrosine (NT)
levels, related to oxidative damage, were doubled in OA patients
when compared to healthy volunteers whereas plasma NT levels
were increased by just about 40% and urinary NT levels did not
differ at all8. As such, discriminating ability in this study increased
from urine, to blood, to SF.
Alsowithout direct comparisonwith the systemic compartment,
the value of SF biomarker analysis for establishing diagnose and
relation to burden of disease can be demonstrated in relatively small
study populations (Table II). San Giovanni et al.39 demonstrated a
clear discriminating ability of interleukin (IL)-6, (monocyte che-
moattractant protein (MCP)-1, and ﬁbronectin-aggrecan complex
(FAC) in SF between groups with increasing degree of arthroscopi-
cally evaluated ankle pathology. To demonstrate this in the SF
compartment they needed only small groups (n ¼ 11, 6, 15, and 4).
The synovial levels of FAC andMCP-1were introduced in amodel to
discriminate between minimal and substantial intra-articular pa-
thology, obtaining 82% speciﬁcity, 63% sensitivity, and 72% accuracy
in predicting the presence of substantial pathology. Also tenascin-C
levels in SF were highly elevated in knee OA patients vs controls
(again in small groups already; n ¼ 8 vs 12, P < 0.001) and were
correlated with markers of cartilage degradation and inﬂamma-
tion6. The authors concluded that tenascin-C in SF may serve as a
marker of joint damage. In a study in knee OA patients with and
withoutﬂare (n¼ 19 vs 25), an algorithmof SFHAconcentration, HA
molecular weight (mw), and protein concentration was highly
discriminating between patients with and without ﬂare
(P < 0.0001)40. Finally, an investigative study on potential SF
markers revealed that a spectrum of markers partly derived from
plasma, expectedly through ultraﬁltration by the synovial tissue,
had inﬂammatory potential and with that could add to low-grade
inﬂammatory activity in the joint41. Clearly SF as compartment to
evaluate biomarkers of cartilage tissue turnover has its advantages.
However, it has to be acknowledged that also serum markers
may have discriminative potential. In an explorative study it was
found that the area under the receiver operating curve (AUC ROC)
for serum levels of ﬁbulin (Fib)3-1 and Fib3-2 were 0.75 and 0.84,
respectively. An AUC ROC value of 0.80e0.90 is considered to begood at separating subjects with a disease from those without.
However, as concluded by the authors, these ﬁndings should be
replicated in larger studies.42
Overall, last year a total of 12 studies reported on SF marker
analyses vs 27 on systemic (serum, plasma, or urine) markers. All 12
were on knee OA, except for one on ankle OA. This is not surprising
as collection of SF will be restricted to the larger joint. As such this
approach does not ‘serve’ generalised OA including the smaller
joints. Interestingly, several of these studies provided data on SF
marker in ‘healthy’ subjects. Despite reluctance to needle aspiration
in healthy joint in general, apparently, also in healthy subjects SF
aspiration is feasible. Although to our opinion the diagnostic ability
and relation with burden of disease of SF biomarkers will outrange
that of systemic markers, none of the studies reported on their
prognostic value.
Inﬂammation vs primary (intrinsic) cartilage tissue damage;
is OA an inﬂammatory disease?
Five studies on systemic markers investigated their prognostic
ability, the ‘highest’ level within the BIPED classiﬁcation. One was
the aforementioned study on the change in COMP on stimulus-
response30. Three studies involved inﬂammation-related markers.
Van Lent and co-workers reported on S100 molecules (alar-
mines) that are predominantly released by activated macrophages,
belonging to the group of damage associated molecular patterns
(DAMPs), and are crucial in innate immunity. They demonstrated
that baseline serum levels of S100A8/A9 in patients with early-
stage knee OA with pronounced radiographic progression of joint
destruction in the subsequent 2 years were increased (19%) as
compared to those without radiographic progression43. The au-
thors suggested S100A8/A9 proteins to be crucially involved in
synovial activation and cartilage destruction during OA and that
high levels may predict joint destruction. Interestingly, Han and co-
workers44 performed proteomic analyses of SF and also identiﬁed
S100 proteins to be upregulated in OA. S100A12 was identiﬁed as a
key biomarker for OA, with diagnostic and/or prognostic value.
We demonstrated a prognostic role of adipokines, with their
potential inﬂammatory roles, as described above32. Stannus and
colleagues evaluated serum levels of high sensitivity (hs) C-reactive
protein (CRP), tumour necrosis factor alpha (TNFa), and IL-6 and
their relations with changes in knee pain over 5 years. Baseline
hsCRP and serum TNFa levels as well as their change over 2.7 years
were associated with increases in knee pain as assessed by the
western Ontario and McMaster universities osteoarthritis index
(WOMAC) score. While hsCRP was associated with increased knee
pain when lying in bed at night and while sitting or lying, sTNFa
and sIL-6were associatedwith knee painwhile standing45. Markers
of inﬂammation seem to perform quit well regarding prognosis of
structural and symptomatic characteristics of OA. This (re-)opens
the discussion of OA as being an (low-grade) inﬂammatory (driven/
accompanied) disease vs a primarily intrinsic degenerative disease.
To the best of our knowledge biochemical markers have not
(yet) been used in decision-making in clinical practice or trials in
OA. This contrasts with the use of biochemical markers in rheu-
matoid arthritis (RA). In a trial, treatment was guided by either
disease activity score (DAS) or by uCTX-II levels. No signiﬁcant
difference in remission was observed between decision-making
according to DAS or uCTX-II levels46. Moreover, recently, a
commercially available biomarker kit (VectraDA) is developed
and used in clinical practice to described disease activity (inﬂam-
mation) in RA (although still to a limited extend and restricted to
the USA). With this kit, disease activity is assessed by use of an
algorithm comprising values of 12 biochemical markers in serum
(SAA, IL-6, TNF-RI, VEGF-A, MMP-1, YKL-40, MMP-3, epidermal
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Several of these makers are not unfamiliar in the OA ﬁeld, unfor-
tunately, VectraDA, including the cartilage originating markers
like MMP-1, -3, and YKL-40 was not (yet) reported to describe
disease severity, viz. joint damage in RA. We are not aware of a
systematic search for an algorithm of a wide-spectrum biomarker
set for OA. Maybe a commercial drive is needed to make this
possible, or the large biomarker OAI and CHECK initiatives be used
may in collaborative effort for such an approach.
Overall, inﬂammatory/immunological markers were among the
relatively ‘best’-performing markers with regard to burden, prog-
nostic and/or treatment efﬁcacy, as is shown in Table I. This obser-
vation ﬁts the general trend of considering OA as an inﬂammatory
disease. Still it is important to realise that inﬂammation may only
explain part of the pathogenesis of OA and that particular inﬂam-
matory OA may be only a speciﬁc subtype (phenotype) of this
disease.
Different phenotypes of disease; can biomarker analyses add
to delineation?
It is often stated that the OA biomarker ﬁeld is hampered by lack
of a gold standard, an unambiguously disease modifying-treatment
e.g., Ref. 27, a detailed qualitative imaging technique e.g., Ref. 48,
and/or a representative animal model of OA e.g., Ref. 49. But prob-
ably even more complicating in this respect is the notion of
different phenotypes in OA50. Expectedly, not all patients will have
the same sequence and involvement of pathogenetic events and
consequently will not respond similarly to a treatment. Biochemical
markers supposedly reﬂect very speciﬁc metabolic pathways of
which the relative importance in the pathogenesis of OA is only
partly known, but need to relate to metabolic pathways that are
speciﬁcally important in the (sub)population tested. In line with
the hypothesis that different OA phenotypes exist, the relative
importance of metabolic pathways may differ between subjects,
between joints, and between disease stages51. Potentially strong(er)
associations of biochemical marker levels with disease parameters
in one speciﬁc phenotype may be obscured by other phenotypes
not showing these associations. The discriminative ability of several
biochemical markers between erosive and non-erosive hand OA (as
discussed above34) may be considered an example of this. Finally,
not only differences in OA between subjects, but also differences in
systemic biochemical marker metabolism (liver and kidney func-
tion) and comorbidities as discussed above, challenge the devel-
opment of robust systemic biochemical marker for the OA
population in general.
Kumm et al. found longitudinal associations between bio-
markers and consecutive components of disease progression in
knee OA. Over the ﬁrst 3 years of follow-up, signiﬁcant associations
were observed between sCOMP and osteophytosis, whereas in the
subsequent 3 years uCTX-II was associated with joint space nar-
rowing (JSN). This is the ﬁrst study to demonstrate associations
between biochemical markers and radiographic parameters
changing over the course of knee OA, illustrating a phasic non-
linear character of OA with periods of progression and stabilisa-
tion51. The study of Fernandez-Moreno and co-workers considered
the concept of different phenotypes a key issue in their biomarker
analyses52. They recognised a role of mitochondria in the patho-
genetic process of OA. They found that patients that carrying the
mtDNA haplogroup H had higher levels of all the studied catabolic
markers of OA than patients carrying the mtDNA haplogroup J. As
such two different mitochondrion-related OA phenotypes could be
deﬁned52. The potential importance of mt haplogroups in OA
phenotype differentiation was reviewed by the same group19. Also
the study of Bos and colleagues reﬂected on different phenotypes ofOA. They consider metabolic health of the study population in
relation to uCTX-II and sCOMP levels53. Studies on EHOA in com-
parison to non-erosive hand OA34might also be counted as a step in
recognising the importance of different phenotypes of OA in
biomarker evaluation.
The aforementioned systems analysis approach described by
Andriacchi and colleagues can be an effective tool for analysing
complex problems, with a diverse range of interacting variables
that affect the overall behaviour of the system. Speciﬁc disease
phenotypes (subtypes) might be detected in response to speciﬁc
provocative stimuli. Such stimulus-response models may offer a
valuable opportunity to probe the in vivo system response that
underlies OA, potentially identifying different phenotypes that may
be relevant in biomarker research30,37. Such an approach may add
to all levels of biomarker (BIPED) classiﬁcation, as the stimulus may
have a differentiated impact (response) in case of presence or
absence (diagnosis) of disease, burden, prognosis (as demonstrated
in the present approach), and even treatment response. Another,
more holistic approach is ‘systems biology’, combining genomics,
transcriptomics, proteomics, and metabolomics platforms. This
might be a future for detecting novel pathways involved in different
phenotypes of OA as reviewed last year5. However, maybe a
stimulus-response approach has advantages, since systems biology
despite years of research in other ﬁelds, is still very costly and
complicated and, although some attempts have been made in the
OA ﬁeld42,54,55 has not yet revealed a solution.
Treatment efﬁcacy evaluated by biochemical marker analyses
In four human studies the efﬁcacy of treatment was accompanied
by changes in biochemical markers. The aforementioned study by
Conrozier on intra-articular visco-supplementation demonstrated
that baseline sHA was moderately but signiﬁcantly predictive of
treatment efﬁcacy at day 90 suggesting that visco-supplementation
may be more effective in patients with more severe synovitis35. In
this study35 and another report from the same open trial89 it was
demonstrated that treatment efﬁcacy was reﬂected by a decrease in
uCTX-II as well as Coll2-1, suggesting a decrease in collagen type II
degradation and inﬂammation by (this) visco-supplementation.
Arthroscopic surgery of 24 patients with knee arthropathy resulted
in a signiﬁcant and persistent decrease in serum keratan sulphate
levels and chondroitin 6 over 4 sulphate levels over a period of 12
weeks56. Subjects inwhomthe efﬁcacyof the surgerywas suboptimal
requiring arthroplasty within 2 years showed signiﬁcantly less
change in keratin sulphate levels as compared to those with a
favourable outcome. Güngen and colleagues demonstrated superi-
ority of mud pack therapy over hot pack therapy in the treatment of
knee OA. Mud pack therapy decreased cartilage loss as evidenced by
decrease in YKL-40 levels, possibly due to the speciﬁc effects of the
minerals found in themud, according to the authors57. Squatexercises
combinedwithwhole-body vibration on a vibrating platform in knee
OA inﬂuenced plasma levels of inﬂammation markers (soluble TNF
receptor (R)1 and R2). In the platform group, there were signiﬁcant
reductions in the plasma levels of both inﬂammatory markers and
self-reported pain as compared to the control group. This was
accompanied by an increase in balance, speed, and distance walked.
The results suggest thatwhole-body vibration training improves self-
perceptionof pain, balance, gait quality, accompaniedbyadecrease in
inﬂammatory markers in elderly subjects with knee OA.58
The future: where to go?
In the OA year in review 2011 it was expected that clinical
application of biomarkers for OA would become increasingly
feasible, and, that the ﬁeld would shift “from the realm of the
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that biomarkers predictive of OA progression at the individual level
would become available in the near future4. Last year it was pro-
claimed that the recent proliferation of post-genomic technologies
would result in rapid growth and progress in biomarker research5.
This year, looking back the past years, we are somewhat less opti-
mistic in our conclusions. Still, we believe that the ﬁeld can be
brought forward (we have to).
One of the ﬁrst steps forward may actually be taking a step back.
A critical review of molecular metabolism in OA and validation of
currently investigated marker molecules in this may be vital and
may lead to new and better markers. It appeared that COMP frag-
ments may be more sensitive for OA than total COMP. A signiﬁcant
increase of particular COMP fragments was noted in serum of OA
patients when assayed with a new enzyme linked immunosorbent
assay (ELISA), while total COMP levels that were assessed with a
commercial COMP ELISA kit did not differ between the OA and
control group. In addition, serum COMP fragment levels were well
correlated with radiographic severity (K-L grade) of OA in men as
well as with progression of surgically-induced OA in mice7. Taking
into account posttranslational modiﬁcations of matrix molecules
might appear another important step forward and may be of good
use in identifying joint and OA speciﬁc biochemical markers.
Healthy and osteoarthritic joints may differ with regard to char-
acteristics that affect these posttranslational modiﬁcations of
extracellular matrix proteins. For example, deamidation of protein
epitopes progresses irreversibly when proteins age and different
levels of matrix turnover between joints may translate into
different levels of deamidation of extracellular proteins of these
joints (i.e., shortened protein lifetime at high turnover rates). As
reviewed last year5, Catterall and colleagues28 demonstrated that in
contrast to total COMP, deamidated COMP (D-COMP) levels were
more prominently decreased in patients undergoing hip replace-
ment than in patients undergoing knee replacement. This apparent
(relative) speciﬁcity of D-COMP for the hip was conﬁrmed by the
observation that D-COMP levels were associated with radiographic
hip but not knee OA severity in 450 subjects.28
Another consideration with regard to taking a step back con-
cerns the relation between the systemic compartment and joint
compartment. Although it is generally appreciated that systemic
biochemical markers would be of better use in clinical practice, in
the developmental phase it might be helpful to start with evalu-
ating SF samples. This better eliminates (diurnal) variability from
systemic metabolism, food intake, comorbidities, turnover of other
connective tissues, involvement of multiple joints, and so on.
Repeated aspiration over time of traumatic knees has provided
valuable results in the past. However, in OA research this might be a
challenge as it is not obvious to take a SF sample from a seemingly
healthy joint, or from joints other than the knee. Possibly ultra-
sound may facilitate knee SF aspiration in case of early complaints
related to knee OA. By taking this step back, creating cohorts in
which SF is obtained in a systematic way, together with serum and
urine, may bring the ﬁeld a further step ahead.
A third consideration is the recognition of OA phenotypes
(subtypes) in identifying and testing biochemical markers. Recently
Kinds et al. demonstrated that different radiographic phenotypes of
OA may exist. The phenotype designated as ‘bone phenotype’ in
which bone changes predominate over cartilage changes, during 5
years follow-up, could be distinguished from the other phenotypes
by clinical and radiographic characteristics at baseline with an AUC
ROC of 0.9159. If such clear phenotypes cannot even be identiﬁed
with, in this case bone, markers, it might be questioned whether
suchmarkers would be of use in a general population. The currently
steadily growing perception of different phenotypes, will expect-
edly facilitate biochemical marker research.Fourthly, the systems biology approach as discussed last year5,
although very costly, might provide steps forward. But even with
such a complex ‘tool’ the previous suggestions remain valid to
our perspective. Different in practice but considering the same
complexity of the bodily system, biomarker level analyses using a
stimulus-response modelling as mentioned above, could increase
our understanding of the interplay between biochemical, structural
and functional variables that inﬂuence the osteoarthritic process37
and add to biomarker development.
Looking ahead, we are optimistic in our expectations, we believe
that the ﬁeld can be brought forward by critically and cautiously
reconsidering our approaches, and making changes forward, one
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